Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 115 от 222

Набира участници Фаза 3

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Melanoma, Cutaneous Malignant

This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma. For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/

Начало: 14.01.2025 Край: 01.10.2031 Възраст: от 18 г.

Canada, Germany, United Kingdom +1 Immatics US, Inc. NCT06743126

Набира участници Фаза 2

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Acute Myeloid Leukemia

This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azacitidine, to determine the dose for Part 2. This determined dose, in combination with venetoclax and azacitidine, will then be further evaluated in Part 2 in 2 cohorts (TP53 mutated and TP53 wild type). Both parts will be conducted in participants with previously untreated CD123+ AML who are ineligible for intensive chemotherapy.

Начало: 14.01.2025 Край: 11.02.2030 Възраст: от 18 г. Лечение

Australia, United States Stemline Therapeutics, Inc. NCT06456463

Набира участници Фаза 2

A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor

TMB-H Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors

The goal of this clinical trial is to determine the efficacy of IMC-001 in metastatic or locally advanced TMB-H solid tumor patients.

Начало: 13.01.2025 Край: 01.08.2029 Възраст: от 19 г.

South Korea ImmuneOncia Therapeutics Inc. NCT06365840

Набира участници Фаза 1

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

Advanced Solid Tumor

This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid tumors.

Начало: 13.01.2025 Край: 01.06.2028 Възраст: от 18 г. Лечение

Australia, United States BioNTech SE NCT06750185

Набира участници Фаза 4

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

Diabetes Mellitus, Type 2 Diabetes Type 2 Diabetes Pre Diabetes

This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD), those with overweight type 2 diabetes (OWD), and normal-weight controls without diabetes (NWC). The study will assess whether adipocyte-directed therapies, specifically pioglitazone and tirzepatide, can improve insulin resistance, adipocyte function, and fat distribution in individuals with NWD. By analyzing the biological mechanisms underlying adipocyte dysfunction, the study aims to provide insights into novel treatment strategies for improving metabolic health in normal-weight individuals with type 2 diabetes.

Начало: 13.01.2025 Край: 15.12.2027 Възраст: 30–70 г.

United States Stanford University NCT06657209

Набира участници Фаза 1/2

Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)

oGHVD

A Double-Masked, Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of d-MAPPS™ Ophthalmic Solution in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGHVD)

Начало: 10.01.2025 Край: 01.12.2026 Възраст: от 18 г.

United States Regenerative Ocular Immunobiologics LLC NCT06852768

Набира участници Фаза 3

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

Type 2 Diabetes

The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.

Начало: 10.01.2025 Край: 01.12.2027 Възраст: 10–17 г.

Argentina, Mexico, United States Eli Lilly and Company NCT06739122

Набира участници Фаза 2

An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures

Focal Onset Seizure Primary Generalized Epilepsy

An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures

Начало: 10.01.2025 Край: 01.07.2025 Възраст: 18–75 г. Лечение

Australia, Spain, United States Praxis Precision Medicines NCT06908356

Набира участници Фаза 1

IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Locally Advanced Solid Tumor

This is a Phase 1 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. The purpose of this study is to identify the MTD/RP2D of IBI3001, and to explore the preliminary efficacy of IBI3001.

Начало: 10.01.2025 Край: 31.12.2027 Възраст: от 18 г. Лечение

Australia, China Innovent Biologics (Suzhou) Co. Ltd. NCT06349408

Набира участници Ранна Фаза 1

Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

Recurrent Glioblastoma

The clinical study of YSCH-01 will adopt an open-label, randomized design, with a planned enrollment of 10 participants with recurrent glioblastoma. Participants will be randomly allocated to the YSCH-01 monotherapy cohort or the YSCH-01 + Atezolizumab combination cohort, with 5 participants in each cohort. The study consists of the following three phases: screening phase, treatment phase, and follow-up phase. The primary endpoint is the 1-year survival rate of participants

Начало: 09.01.2025 Край: 28.02.2027 Възраст: от 18 г.

China Huashan Hospital NCT07538128

Набира участници Фаза 2

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

The study is a two-part (Part A and Part B) randomized double-blind vehicle-controlled multi-center study in a total of 174 participants with moderate to severe glabellar lines. The objective of this study is to test the safety, efficacy, immunogenicity of YY003, and compare to vehicel control, in improving the appearance of moderate to severe glabellar lines.

Начало: 09.01.2025 Край: 01.10.2025 Възраст: от 18 г. Лечение

Australia Chongqing Claruvis Pharmaceutical Co., Ltd. NCT06481475

Набира участници Фаза 1/2

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

NSCLC (Advanced Non-small Cell Lung Cancer)

This Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with NSCLC having EGFR and/or HER2 mutations. Phase 1 will determine the recommended Phase 2 dose (RP2D) and, if applicable, the maximum tolerated dose (MTD) of BH-30643. Phase 2 will further evaluate the antitumor efficacy and safety in specified cohorts determined by EGFR/HER2 mutation subtypes and/or treatment history at the RP2D, as well as the population PK.

Начало: 09.01.2025 Край: 31.07.2029 Възраст: от 18 г. Лечение

Australia, Canada, Hong Kong +6 BlossomHill Therapeutics NCT06706076

Набира участници Фаза 3

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis

Arthritis, Psoriatic

The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in biologic-experienced participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

Начало: 09.01.2025 Край: 18.10.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +19 Janssen Research & Development, LLC NCT06807424

Набира участници

Use of Eye Tracking to Aid in Autism Risk Detection

Autism

The study will use a non-invasive remote eye-tracking system (Eyelink Portable Duo) to acquire a short series of eye-tracking measures.

Начало: 08.01.2025 Край: 30.04.2027 Възраст: 12–48 г.

United States Indiana University NCT06471504

Набира участници Фаза 2/3

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Non-small Cell Lung Cancer

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.

Начало: 07.01.2025 Край: 01.03.2030 Възраст: от 18 г. Лечение

Australia, Belgium, China +12 BioNTech SE NCT06712316

Набира участници Фаза 4

International Care Bundle Evaluation in Cerebral Hemorrhage Research

Intracerebral Hemorrhage Intracerebral Haemorrhage Intraventricular Hemorrhage Stroke +1

Spontaneous intracerebral haemorrhage (ICH) accounts for approximately 10-15% of all strokes but stands for 50% of stroke-related morbidity and mortality. Approximately half of all patients with ICH have a decreased level of consciousness at hospital admission. Despite this, intensive care and neurosurgical interventions are uncommon. A study conducted in low- and middle-income countries has demonstrated a beneficial effect of a treatment package consisting of early intensive blood pressure lowering, as well as the treatment of pyrexia and elevated blood glucose levels. The I-CATCHER team is now planning to conduct a similar study in Sweden and Australia, as well as in other high-income countries. The study has a clear focus on implementation, aiming to improve treatment and prognosis for patients with ICH within a few years. The purpose of I-CATCHER is to investigate whether a structured treatment package (Care Bundle) improves 3-month prognosis in patients with spontaneous ICH compared to standard care.

Начало: 07.01.2025 Край: 01.07.2027 Възраст: от 18 г. Лечение

Australia, Canada, Hong Kong +5 Region Skane NCT06429332

Набира участници

Mediators and Moderators of Auditory Training

Hearing Handicap

The goal of this clinical trial is to learn how Auditory Training (AT) may help people better understand speech in noisy environments. As people get older, it becomes harder for them to hear speech clearly when there is background noise. This can be frustrating, and it can affect their independence and quality of life. AT is often used to support people with and without hearing loss, especially when a person is not a good candidate for a hearing aid or when amplification from a hearing aid does not improve performance. The investigators want to gather reliable data to understand how AT works and what affects its success. The main questions the trial aims to answer are: * How do different types of sounds influence the effectiveness of auditory training? * Which auditory training approaches are most successful in improving speech understanding? * How do personal traits impact the results of auditory training? The investigators will study a large and diverse group of 1,260 participants, including both young and older adults, to evaluate various auditory training approaches. You will: * Take part in auditory training sessions that include different types of auditory tasks. * Complete tests that measure how well they understand speech in both quiet and noisy settings. * Complete surveys on personal data like demographics, hearing challenges and other factors to help researchers understand what might influence training results. The investigators will measure and compare the results of these approaches to find out which ones are most effective. This could help people who are at risk of cognitive decline, like those at risk for Alzheimer's disease.

Начало: 06.01.2025 Край: 31.05.2027 Възраст: 18–85 г.

United States Northeastern University NCT06812273

Набира участници Фаза 2

SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）

Unresectable Locally Recurrent Rectal Cancer

This is a prospective study to delve into the therapeutic benefits of combining stereotactic body radiation therapy (SBRT) with PD-1 monoclonal antibody treatment for patients with unresectable locally recurrent rectal cancer (ULRRC). Our aim is to ascertain the safety of this approach and to offer robust, evidence-based medical guidance for the management of ULRRC using this innovative combination therapy. Researchers will combine SBRT with PD-1 for ULRRC to see if this treatment can provide a benefit of survival. Participants will: 1. Receive chemotherapy combined with PD-1 therapy for 1 cycle → SBRT treatment → Chemotherapy combined with PD-1 therapy for 3-6 cycles (assessment 6 weeks after SBRT treatment) → Surgery/Maintenance therapy. 2. Visit the clinic once every 3 months for checkups and tests

Начало: 06.01.2025 Край: 30.11.2027 Възраст: 18–75 г.

China Sixth Affiliated Hospital, Sun Yat-sen University NCT06767007

Набира участници Фаза 3

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Breast Cancer

The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease. Approximately half of the participants will receive PF-07220060 plus letrozole while the other half of participants will receive the investigator's choice of treatment plus letrozole. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

Начало: 06.01.2025 Край: 29.12.2037 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +25 Pfizer NCT06760637

Набира участници

Erector Spinae Plane Block in Laparoscopic Colorectal Cancer Surgery

Kolon Kanseri

Our study will compare patients who underwent laparoscopic surgery for colorectal cancer with and without Erector Spinae Plane Block in terms of renal blood flow and renal function tests. In our study, which will be conducted by dividing patients into two groups, the investigators aim to demonstrate the effects of the erector spinae plane block on renal physiology by simultaneously monitoring renal blood flow during the intraoperative period using near-infrared spectroscopy and monitoring renal function in the postoperative period using NGAL, serum creatinine, and eGFR.

Начало: 05.01.2025 Край: 12.04.2026 Възраст: 18–75 г.

Turkey (Türkiye) Kayseri City Hospital NCT07297433

1 … 113 114 115 116 117 … 222